Blood plasma serves as key raw material in blood product industry. In August
2011, the shut-down of 16 plasma collection stations in Guizhou province,
China resulted in a YoY decline of 15% in plasma volume and further
intensified the tight supply of raw material plasma. But when it comes to the
lot release volume, the blood product output in China grew as high as 15.4%
YoY in 2011, and the market size rose 22% YoY to around RMB11.6 billion.
Additionally, in consideration of 12th Five-Year Plan for Doubling Blood
Product Supply proposed by the Minister of the Ministry of Health at the end
of 2011, the issuance of Notice of the Ministry of Health on Management of
Plasma Collection Stations in early 2012, and the domestic market demand &
supply, the blood product market size in China is expected to maintain a high
growth rate of over 20% in the five years to come.
However, the low degree of industry concentration, the companies' weak R&D
capabilities, short supply of raw material plasma and low plasma utilization
rate affect the development of Chinese blood product industry to some extent.
The blood products released in overseas market divide into around 40
varieties, and the international blood product giants can extract about 15
varieties of blood products from plasma, while among Chinese companies,
Beijing Tiantan Biological Products Co., Ltd. can produce at most 11 varieties
from plasma. Moreover, Chinese blood product market is principally
concentrated on human albumin and human immunoglobulin (pH4) for intravenous
injection which pose low requirements on technologies. In 2011, the lot
release volume of the two products made up 53.4% and 16.8% of the total
release volume respectively.
Product Structure of Blood Products in China (by Lot Release Volume), 2009-2011
Source: National Institute for Food and Drug Control;
7 Regional Institutes for Drug Control;
ResearchIn China: “China Blood Product Industry Report, 2011-2012”
Blood coagulation factor and thrombin products feature the largest demand gap
in China, but there are less domestic supply and fewer producers. In 2011, the
manufacturers of Human Coagulation Factor VIII in China just include Shanghai
RAAS Blood Products, Green Cross China and Hualan Biological Engineering Inc.,
with lot release volume adding up to 350,000 bottles, and the producers of
Human Prothrombin Complex are Hualan Biological Engineering Inc., Shanghai
RAAS Blood Products and Shanghai Xinxing Medicine, with lot release volume
totaling 200,000 bottles. Essentially, subsidiaries under China National
Biotech Group and other Groups that possess production capacity and obtain
governmental approvals in Coagulation Factor VIII and IX do not conduct
production in recent years. With the intensifying contradiction between supply
and demand, the government may launch intervention measures to enable the
enterprises with the approval to restart the manufacturing of these products
to raise overall supply of products of this sort.
Although taking such factors like home market demand into account, China has
allowed the import of some blood products, but the imports are confined to
human albumin and recombinant coagulation factor. Moreover, blood product
manufacturing is a sector with no allowance for foreign capital. The imported
human albumin almost makes up 50% market share, and the proportion reached
43.3% in 2011.
Following the tougher conflict between supply & demand and the loosening of
policies in China, foreign brands quicken their pace of tapping into Chinese
market. In May 2012, SFDA approved the release of Baxter's ADVATE (Recombinant
Human Coagulation Factor VIII for injection) in China which was another
foreign brand of coagulation factor after the imported Bayer's Recombinant
Coagulation Factor VIII in 2007. Moreover, Pfizer is applying for quick
approval program for its Recombinant Coagulation Factor IX (obtained from
The report resolves around the followings:
The plasma volume, distribution of plasma stations, market size and supply
& demand of Chinese blood product industry;
Competition pattern, policy climate and import & export of Chinese blood
Market supply & demand and competitive landscape of 8 blood products such
as human albumin, human immunoglobulin (pH4) for intravenous injection and
coagulation factor, etc.
Status quo, operation, plasma collection station and product lot release
volume of 9 Chinese blood product manufacturers
STUDY GOAL AND OBJECTIVES
This report provides the industry executives with strategically
significantcompetitor information, analysis, insight and projection on
thecompetitive pattern and key companies in the industry, crucial to
thedevelopment and implementation of effective business, marketing andR&D
To Eestablish a comprehensive, factual, annually updated and
cost-effective information base on market size, competition patterns, market
segments, goals and strategies of the leading players in the market, reviews
To assist potential market entrants in evaluating prospective acquisition
and joint venture candidates.
To complement the organizations' internal competitor information gathering
efforts with strategic analysis, data interpretation and insight.
To suggest for concerned investors in line with the current development of
this industry as well as the development tendency.
To help company to succeed in a competitive market, and
Both primary and secondary research methodologies were used in preparing this
study. Initially, a comprehensive and exhaustive search of the literature on
this industry was conducted. These sources included related books and
journals, trade literature, marketing literature, other product/promotional
literature, annual reports, security analyst reports, and other publications.
Subsequently, telephone interviews or email correspondence was conducted with
marketing executives etc. Other sources included related magazines, academics,
and consulting companies.
The primary information sources include National Institutes for Food and Drug
Control, local Institutes for Drug Control and listed companies etc .
Table of Contents
Table of Contents
1. Profile of Blood Products
1.3. Recombinant Blood Products
1.4. Industry Chain
2. Overview of China Blood Products Industry
2.1. Market Size
2.2. Development Status
2.3. Market Supply & Demand
2.4. Market Competition
2.5. Operating Environment
2.5.1. International Market
2.5.3. Domestic Biopharmaceutical Market
2.6. Import & Export
3. Blood Product Market Segments in China
3.1. Human Albumin
3.1.1. Supply & Demand
3.1.2. Competition Pattern
3.2. Human Immunoglobulin (pH4) for Intravenous Injection